Urinary Bladder, Overactive: all 864 studies

Page 8 of 9. Open to participants first (125), then studies with results posted, then the rest; newest registration first within each.

• Vesitirim™ in Men Postmarketing Observational StudyCompletedNCT01639794
• Onabotulinumtoxina Intradetrusorial Injections and NGF ExpressionCompletedNCT01629433
• Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic DrugStatus unknownNCT01627145Not applicable
• Premarin Versus Toviaz for Treatment of Overactive BladderStatus unknownNCT01613170Phase 4
• Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01604928Phase 2
• Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord LesionsTerminatedNCT01598103Phase 2
• Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency SymptomsStatus unknownNCT01595152Not applicable
• Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive BladderCompletedNCT01578304Phase 4
• Painless Laser Therapy for Overactive BladderStatus unknownNCT01569061Not applicable
• A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy VolunteersCompletedNCT01566760Phase 1
• Colonization of the Female Urethra With Mycoplasma Hominis, Ureaplasma Urealyticum, Chlamydia Trachomatis, or Neisseria Gonorrhea in Patients With Lower Urinary Tract SymptomsCompletedNCT01559623
• Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive BladderCompletedNCT01558856Not applicable
• An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional UrodynamicsTerminatedNCT01540786Phase 1
• Study of Overactive Bladder in Women With ProlapseStatus unknownNCT01540214
• Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive BladderCompletedNCT01539707Phase 1
• Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor OveractivityCompletedNCT01530620Phase 3
• Vaginal Electrical Stimulation Versus NeuromodulationCompletedNCT01525485
• Pharmacokinetics and Relative Bioavailability StudyCompletedNCT01521767Phase 1
• Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive BladderCompletedNCT01515722Not applicable
• Propiverine Hydrochloride Extended-Release Capsule for Overactive BladderCompletedNCT01512004Phase 3
• Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder SyndromeCompletedNCT01503580Not applicable
• Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder PatientsCompletedNCT01499069Not applicable
• Post Marketing Survey of Vesicare in JapanCompletedNCT01489709
• Efficacy and Safety of Gabapentin in Treating Overactive BladderCompletedNCT01486706Phase 2/3
• Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive BladderTerminatedNCT01464372Phase 3
• A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.CompletedNCT01458197Phase 2
• Observational Study to Estimate the Dry Mouth in OAB Patients With SolifenacinCompletedNCT01437670
• Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive BladderStatus unknownNCT01423838Phase 4
• Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive BladderStatus unknownNCT01409512
• "Swallow my Urine Back" : Inhibition of Detrusor Overactivity by Swallowing ManeuverCompletedNCT01408771
• A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin TreatmentCompletedNCT01318837Phase 4
• A Study Measuring and Tracking Changes in Overactive Bladder (OAB) MedicationWithdrawnNCT01317810
• Therapy of the Overactive Bladder SyndromeCompletedNCT01314781Phase 4
• Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and FrequencyCompletedNCT01294982Phase 2
• Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and AdolescentsCompletedNCT01262391Phase 1
• Investigation of the Suburothelial Myofibroblast Network and of Smooth Muscle Function and Control in the Human Urinary Outflow TractStatus unknownNCT01227447
• A Clinical Study for Magnetic Stimulation of the Posterior Tibial Nerve in Overactive BladderCompletedNCT01214265Not applicable
• Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral StentsWithdrawnNCT01210859
• Grouptraining for Overactive Bladder in AdultsCompletedNCT01187082Not applicable
• Effect of Pulse Rate Changes on Clinical OutcomeCompletedNCT01164280Not applicable
• Screening Method in Sacral NeuromodulationCompletedNCT01130415
• Bryophyllum Versus Placebo for Overactive BladderCompletedNCT01127126Phase 2
• A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to TreatmentCompletedNCT01122563
• Reproducibility Study of Overactive Bladder Symptom Score [OABSS]CompletedNCT01122550
• Basic Sensations Coming From the BladderCompletedNCT01114412
• A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)TerminatedNCT01099345
• Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor OveractivityCompletedNCT01091727Phase 3
• OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ERStatus unknownNCT01050114Phase 3
• Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive BladderCompletedNCT01047046
• Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) PatientsWithdrawnNCT01043848Not applicable
• A Study of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01043666Phase 3
• Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in FemalesCompletedNCT01042119
• Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal SubjectsCompletedNCT01029015
• A Confirmatory Study of KUC-7483 in Patients With Overactive BladderCompletedNCT01004315Phase 3
• Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor OveractivityCompletedNCT01003457
• Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive BladderWithdrawnNCT01003405Phase 3
• Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder PatientsCompletedNCT00985387
• Overactive Bladder (OAB) Drink Advice StudyWithdrawnNCT00982241Not applicable
• Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without UrgencyCompletedNCT00979472Phase 4
• Cohort Study: Perceptual Urge SensationCompletedNCT00971646
• A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive BladderCompletedNCT00966004Phase 3
• Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)CompletedNCT00922506Phase 4
• FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months PeriodCompletedNCT00921245
• The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsCompletedNCT00914667Phase 1
• Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive BladderCompletedNCT00912314Not applicable
• The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy SubjectsCompletedNCT00911235Phase 1
• Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive BladderCompletedNCT00903045Phase 4
• A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy SubjectsCompletedNCT00902681Phase 1
• Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder PatientsCompletedNCT00902421Phase 4
• A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy SubjectsCompletedNCT00902187Phase 1
• Reproducibility Study of Over Active Bladder Symptom Score [OABSS]CompletedNCT00901251
• Anticholinergic Therapy for Overactive Bladder in Parkinson's DiseaseCompletedNCT00892450Not applicable
• A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 WeeksCompletedNCT00884104Phase 4
• Microorganism in Overactive Bladder PatientsCompletedNCT00883818Phase 4
• Study of ONO-8539 in Patients With Overactive BladderCompletedNCT00876421Phase 2
• A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy SubjectsCompletedNCT00856570Phase 1
• 516-BOTOX Urinary Incontinence DetrusorCompletedNCT00850733
• Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor OveractivityTerminatedNCT00845338Phase 2
• A Long-term Study of YM178 in Symptomatic Overactive Bladder PatientsCompletedNCT00840645Phase 3
• Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired VoidingStatus unknownNCT00839969Not applicable
• Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive BladderCompletedNCT00836381Phase 4
• Botulinum A Toxin in Patients With Parkinson's DiseaseStatus unknownNCT00822913Phase 4
• The Effect of Position on Urge Sensation in Volunteers and in Patients With Overactive Bladder SyndromeStatus unknownNCT00821314
• A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031CompletedNCT00814736Phase 1
• Pulsed Electromagnetic Stimulation for Treatment of Overactive BladderTerminatedNCT00805779Not applicable
• Solifenacin Succinate Versus Tolterodine 4mg Once DailyCompletedNCT00802373Phase 3
• Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency SymptomsCompletedNCT00801944Phase 3
• Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor OveractivityCompletedNCT00800462Phase 4
• Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive BladderCompletedNCT00795925Phase 2
• Post Marketing Surveillance Study on Emselex After Launch in GermanyCompletedNCT00786448
• A Safety Extension Study of DR-OXY-301CompletedNCT00782769Phase 3
• Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive BladderTerminatedNCT00780832Not applicable
• Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.CompletedNCT00775281
• Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive BladderWithdrawnNCT00773552Phase 4
• Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic HyperplasiaCompletedNCT00771394Phase 4
• Caffeine Reduction and Overactive Bladder SymptomsTerminatedNCT00754260Not applicable
• Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive BladderCompletedNCT00746681Phase 2
• A Phase II Study of KUC-7483 in Patients With Overactive BladderCompletedNCT00742833Phase 2
• Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) PatientsCompletedNCT00730535Phase 4
• A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive BladderCompletedNCT00699049Phase 4

← Urinary Bladder, Overactive overview